Loading news...
Medline (NASDAQ: MDLN - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Profitability This table compares Medline and Profusa's net margins, return
After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections
CapsoVision (NASDAQ: CV - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Insider and Institutional Ownership 9.8% of Profusa shares are
Predictive Oncology (NASDAQ: AGPU - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a breakdown of recent
With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million BERKELEY, Calif, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has received several purchase orders for the Lumee™ tissue oxygen monitoring system from its growing network of European distributors and expert physician customers. With strong underlying market demand, Profusa increased its internal projections, and is subsequently increasing its revenue guidance range for 2026, to $1.5 million to $3 million compared to a previously announced range of $500 thousand to $2 million.
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product
Profusa (NASDAQ: PFSA - Get Free Report) and Nanovibronix (NASDAQ: FEED - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends. Insider and Institutional Ownership 9.8% of Profusa shares are
Profusa (NASDAQ: PFSA - Get Free Report) and Nanovibronix (NASDAQ: FEED - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Risk and Volatility Profusa has a beta of -0.14,
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual's biochemistry, has entered into a know-how agreement with Mayo Clinic. The collaboration entails investigation of high impact clinical applications of Profusa's oxygen monitoring technologies for new product development and commercialization.
Carlsmed (NASDAQ: CARL - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability. Institutional and Insider Ownership 9.8% of Profusa shares are
Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Insider and Institutional Ownership 54.7% of Perspective Therapeutics
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-seventy-five (1:75) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on February 9, 2026, and the Company's common stock will open for trading on The Nasdaq Global Market on February 9, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X 207.
Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the presentation of positive US-study clinical trial results at Leipzig Interventional Course in Leipgzig, Germany on Wednesday, January 28, 2026. The study, conducted at the University of California San Francisco, San Francisco VA Medical Center, and San Francisco General Hospital, showed Lumee oxygen tissue monitoring is a safe and effective method for long term monitoring of peripheral artery disease (PAD) patients.
Carlsmed (NASDAQ: CARL - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings. Valuation and Earnings This table compares Carlsmed and Profusa"s
Profusa, Inc. (NASDAQ: PFSA) stock rallied on Friday as the company is launching its Healthcare Research version of the Lumee tissue oxygen monitoring system.
Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY, Calif, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces the launch of its Healthcare Research version of the Lumee tissue oxygen monitoring into the contract research organizations (CRO) market. This strategic step is expected to generate immediate service-based revenue.
Profusa (NASDAQ: PFSA - Get Free Report) and Shoulder Innovations (NYSE: SI - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability. Valuation and Earnings This table compares Profusa and
Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces a collaboration with Theodosios Bisdas, M.D., Ph.D., FACS, Head of Clinic of Vascular Surgery, Athens Medical Center, Greece, and previously Associate Professor for Vascular Surgery, Universitätsklinikum Münster, Germany.
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union
Profusa Inc. (NASDAQ: PFSA) shares soared on Tuesday after the company announced the restructuring of its debt and a reduction in potential shareholder dilution, sparking a wave of speculative buying for the digital health company.